Literature DB >> 1343619

Salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoring.

R Gorodischer1, G Koren.   

Abstract

Studies suggest that saliva could be used instead of blood in the therapeutic monitoring of many drugs. This has distinct advantages in pediatrics and neonatology as saliva sampling is painless and spares blood. Stimulation of saliva secretion with a chemical stimulus (i.e. citric acid applied over the tongue) facilitates the study of younger patients. Secretory and reabsorptive processes which take place in the ductal system of the salivary glands, and the rate of flow of the secretion play major roles in the determination of the concentration of solutes in saliva. Drug passage into saliva follows the general principles of movement of drugs across biologic membranes. Only the unbound fraction of the drug in plasma is available for diffusion into saliva and a relationship exists between saliva pH and the saliva/plasma concentration ratio of many polar drugs (tolbutamide, propranolol, procainamide, etc.). However, deviations from the pH theory exist and the inter -and intra-individual variations in saliva/plasma concentration ratios of salicylate and procainamide cannot be explained solely on the basis of fluctuations of salivary pH; on the other hand, a useful relationship exists between plasma and saliva phenobarbital concentrations with no need to correct for saliva pH. The use of stimulated saliva has several advantages over resting saliva: a larger volume of the sample is obtained, the pH gradient between plasma and saliva is smaller, the variability in saliva/plasma concentration ratios of some drugs is narrowed, and less specimens are too viscous or discolored to allow drug analysis. Thorough rinsing of the mouth is required prior to saliva sampling as remnants of orally administered medicines may contaminate saliva specimens and give spuriously high values. Deviation from a simple but strict methodology accounts for some of the discrepancies found in the literature. Studies in children uniformly recommend saliva for therapeutic monitoring of phenytoin, carbamazepine and phenobarbital. Saliva sampling for therapeutic monitoring of ethosuximide, primidone and digoxin in infants and children, and of theophylline and caffeine in the neonate is promising, but little pediatric experience is available as yet. The value of saliva in therapeutic monitoring of theophylline in children is still controversial. Little of highly polar compounds such as aminoglycosides, and of polar highly protein bound drugs such as valproic acid is present in saliva. More data are still needed on the excretion of drugs in saliva in infants and in acutely ill children, and few data exist in the premature and full-term neonate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1343619     DOI: 10.1159/000457481

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  11 in total

1.  Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?

Authors:  Janet Hardy; Ross Norris; Helen Anderson; Angela O'Shea; Bruce Charles
Journal:  Support Care Cancer       Date:  2011-04-15       Impact factor: 3.603

Review 2.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 3.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

4.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

Review 5.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 6.  Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Authors:  Mwlod Ghareeb; Fatemeh Akhlaghi
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

7.  Digoxin concentration in saliva and plasma in infants, children, and adolescents with heart disease.

Authors:  Eli Zalzstein; Nili Zucker; Matityhau Lifshitz
Journal:  Curr Ther Res Clin Exp       Date:  2003-11

8.  A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans.

Authors:  Grace O Gbotosho; Christian T Happi; Omowunmi Lawal; Abayomi Sijuade; Akin Sowunmi; Ayoade Oduola
Journal:  Malar J       Date:  2012-02-27       Impact factor: 2.979

9.  Saliva versus plasma bioequivalence of rusovastatin in humans: validation of class III drugs of the salivary excretion classification system.

Authors:  Nasir Idkaidek; Tawfiq Arafat
Journal:  Drugs R D       Date:  2015-03

Review 10.  Saliva--a diagnostic window to the body, both in health and in disease.

Authors:  Maria Greabu; Maurizio Battino; Maria Mohora; Alexandra Totan; Andreea Didilescu; Tudor Spinu; Cosmin Totan; Daniela Miricescu; Radu Radulescu
Journal:  J Med Life       Date:  2009 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.